{$CCXI} St. Gallen, Switzerland, 19 January 2022 – Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis.